Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 15 mg - tablet, uncoated - excipient ingredients: purified water; povidone; potato starch; ethanol; docusate sodium; magnesium stearate; lactose monohydrate; colloidal anhydrous silica - for temporary relief of acute moderate pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - bisoprolol fumarate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; iron oxide red; maize starch; microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - bisoprolol fumarate, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; crospovidone; magnesium stearate; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; pregelatinised starch; crospovidone; microcrystalline cellulose; meglumine; purified water; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 10.42 mg (equivalent: rosuvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; pregelatinised starch; meglumine; purified water; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; meglumine; pregelatinised starch; microcrystalline cellulose; purified water; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 5.21 mg (equivalent: rosuvastatin, qty 5 mg) - tablet, film coated - excipient ingredients: meglumine; lactose monohydrate; purified water; pregelatinised starch; magnesium stearate; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 5.21 mg (equivalent: rosuvastatin, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; meglumine; lactose monohydrate; pregelatinised starch; purified water; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 20.84 mg (equivalent: rosuvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; purified water; lactose monohydrate; microcrystalline cellulose; meglumine; pregelatinised starch; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.